Normalization of enhanced fear recognition by acute SSRI treatment in subjects with a previous history of depression

Am J Psychiatry. 2004 Jan;161(1):166-8. doi: 10.1176/appi.ajp.161.1.166.

Abstract

Objective: The present study aimed to 1) assess facial expression recognition in subjects with a previous history of major depressive disorder relative to subjects with no history of depression and 2) characterize the effects of acute citalopram infusion on recognition performance for both groups.

Method: Unmedicated euthymic women with a history of major depression and matched comparison subjects with no history of depression were given a facial expression recognition task following intravenous infusion of saline or citalopram (10 mg) in a double-blind, between-group design.

Results: Following saline infusion, subjects with a previous history of depression showed a selectively greater recognition of fear relative to the subjects with no history of depression. The abnormal fear processing observed in the subjects with a previous history of depression was normalized following citalopram infusion, an effect that was opposite to that seen with the subjects with no history of depression.

Conclusions: These results suggest that increased recognition of fear is a trait vulnerability marker for depression and that this is normalized following a single dose of citalopram.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial

MeSH terms

  • Acute Disease
  • Adult
  • Citalopram / pharmacology*
  • Citalopram / therapeutic use
  • Depressive Disorder, Major / diagnosis
  • Depressive Disorder, Major / drug therapy*
  • Depressive Disorder, Major / psychology*
  • Diagnostic and Statistical Manual of Mental Disorders
  • Double-Blind Method
  • Facial Expression*
  • Fear*
  • Female
  • Humans
  • Middle Aged
  • Recognition, Psychology / drug effects*
  • Selective Serotonin Reuptake Inhibitors / pharmacology*
  • Selective Serotonin Reuptake Inhibitors / therapeutic use

Substances

  • Serotonin Uptake Inhibitors
  • Citalopram